A multicenter phase II trial of nab‐paclitaxel and capecitabine in HER‐2 negative and triple‐ negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
Mariangela Ciccarese(Ospedale Vito Fazzi), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Roberto Bordonaro(Ospedale Garibaldi), Saverio Cinieri(Ospedale A. Perrino), Salvatore Pisconti(Ospedale SS. Annunziata), Giuseppina Cilenti(Casa Sollievo della Sofferenza), Evaristo Maiello(Casa Sollievo della Sofferenza), Palma Fedele(Ospedale A. Perrino), Antonio Febbraro(Fatebenefratelli Hospital), Antonio Rinaldi, Giovanni Bozza(Centro di Riferimento Oncologico della Basilicata), Laura Orlando, Vito Lorusso, Giuseppe Colucci, R. Forcignanò(Ospedale Vito Fazzi), Nicolò Borsellino(Ospedale Buccheri la Ferla Fatebenefratelli), S. Romito(Ospedali Riuniti di Foggia), Giammarco Surico(Ospedale Vito Fazzi), Paola Schiavone(Ospedale A. Perrino), Michele Aieta(Centro di Riferimento Oncologico della Basilicata), V. Saracino(Ospedale Vito Fazzi)
Cited by 0
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
|Journal of Clinical Oncology|2022|231
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
|Annals of Oncology|2009|205